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Abstract

Outcome assessment has been used to evaluate the length of ueatment needed and has been
disputed for some time. Changes within both mental health and health insurnnce companies have
contributed to a trend toward time-limited therapy and the optimal number of sessions has
become a cenual issue. This study sought to ex.tend research in the area of treatment outcome.
Specifically. it examined the efficacy of psychotherapy after five and ten sessions on the
subjective well-being of university students.
Three hypotheses were tested in th.is study: (1) Subjective Well-Being scores (as measured
by the Outcome Questionnaire-45. l l) for the treatment group will be significantly higher than
those of the control group on the mid and post-tests. (2) Subjective Well-Being scores will be
higher for the treatment group subjects tested after five, and ten sessions of individual
psychotherapy than the scores of the same subjects on the pretest. (3) Subjective Well-Being
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scores will be higher for the treatment group subjects tested after ten sessions than the scores of the
same subjects after five sessions. The results did not support the three hypotheses as clinically
significant change was not demonstrated.
When time was compared to group and gender, there were interaction effects. There was a
quadratic effect on the interpersonal Relationships scale and a quadratic effect was found when
time. group and sex were compared on the Social Role Performance scale. Chi-square analyses
were performed and the interpersonal Relationships scale, F(l,19)=3.446; p=.079, approached
significance. Although there were no significant group effects found when the two treatment
groups were compared, there were three quadratic effects and interaction effects. ·
Future dose-effect studies may benefit from taking their treatment group from a clinical
s<1mple. Using a more diverse sample would also be a beuer representative of the greater
population. ln addition, it is proposed that dose-effect studies examine the effects of more or less
therapy for a particular problem and avoid seeking to show a particular treatment duration as
optimal.
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Chapter 1
lntroduction

Outcome studies attempt to analyze the effects of psychotherapy and its potencial for
alleviating different types of mental problems (Lindfors, et al., 1995). Outcome assessment has
been practiced since the I 930's (Lambert, Okiishi, Finch, & Johnson, 1998) and has changed with
the practice of psychology. Conte (1997) wrote
Psychotherapy outcome research has evolved substantially, both conceptually and
methodologically. since Eysenck's 1952 controversial evaluation of its effectiveness. Since
the I 950's and early '60s, we have moved from the relatively unsophisticated question of
whether psychotherapy of a nonspecific nature and applied to heterogeneous patient
samples can effectively produce personality change to more complex. questions. (p. 445)
Some of these more complex. questions have led to studies finding that psychotherapy can lead to a
decrease in utilization of medical care following psychotherapy (Gabbard, Lazar, Hornberger, &
Spiegel, 1997; Mumford, Schlesinger, Glass, Patrick, & Cuerdon. 1984). Outcome studies meet
many needs. Mirin and Namerow ( 199 I) affirmed that "Treatment outcome studies, although
difficult to design and carry out, are essential in demonstrating the efficacy of psychiatric
treatmenc, rationalizing clinical decision making, and encouraging public support for the
availability of appropriate, cost-effective care for the mentally ill" {p. 1007).
Outcome assessment has been used to evaluate the length of treatment needed. This use of
outcome assessment has been disputed for some time. Strassberg, Anchor, Cunningham and
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Elkins ( 1977) wrote "Mental health practitioners are increasingly under fire by consumer
advocates and others to demonstrate the value of their services. A central issue in this debate
concerns the optimal length (many vs. few sessions) of counseling" (p. 477). The issue of
treatment duration became more than a debate when the rising healthcare costs of the early I 980's
led to the era of accountability and managed mental health care systems (Wells, Burlingame.
Lamben. Hoag. & Hope, 1996).
At the same time, changes within both mental health and health insurance companies have
contributed to a trend toward time-limited therapy which seems to have begun in the early 80's
(Gyorky, Royalty, & Johnson, 1994). In 1992 the Joint Commission on the Accreditation of
Healthcaie Organizations {JCAHO) moved to the Continuous Quality Improvement model which
required that ongoing monitoring of patient care and improvement be added to the existing
outcome assessment procedures (Burlingame, Lamberl, Reisinger. Neff, & Mosier, 1995). This
model has helped some practitioners to increase their effectiveness.
More recently, the mental health field's understanding has gained depth concerning the
impact of psychotherapy on individuals. Gabbard et al .. ( 1997) wrote

ln the last decade or so, the emphasis in the mental health field has shifted away from cost
offset to a more complex understanding of the economic impact of psychosocial
interventions. One factor in this shift has been the recognition that the concept of cost
offset tends to ignore the effects of psychiatric disorder on the quality and quantity of life.
Inherent in the concept of cost offset is the notion that treating mental illnesses is only
beneficial because it reduces overall costs of medical care. (p. 147-148)
Since that time. treatment outcome has come to mean different things for different groups. Lowry
and Ross ( 1997) wrote "discrepancies may also be attributable to differences in outcome
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criteria used by therapists (i.e., clinically significant change), third-party payers (i.e., medically
necessary), and clients (i.e., symptom relief)" (p. 276). Despite this, everyone seems to agree that
the need for accountability, and the practical constraints of applied science drive current outcome
assessment efforts (Lambert et al., 1998).
Treatment and Cost Management
Practitioners have been frustrated by this trend and the increasing emphasis on cost
management. Psychologists have complained of a decline in emphasis on quality health care and a
loss of decision making capacity. These changes have now affected psychotherapists working in
mos! settings. Schaeffer ( l 998) wrote "Finding effective and economical interventions in brief
therapy has become a challenge for therapists of all orientations needing 10 make noticeable
progress within a short period and to achieve positive, measurable outcomes" (p.14).
Some psychologists have proposed that the over-emphasis on cost containment be stopped
and clinical decision making be returned to the psychologist. Mirin and Namerow (1991) wrote
"The mental health industry must now assume responsibility for developing its own costcontainment suategies, lest others in the executive and legislative branches of government, as well
as in the private sector, develop them independently" (p. 1007). In fact, these limitations are being
imposed already. A limit of 10-20 outpatient mental health visits per year is standard and enforced
by many managed care organizations and state/federal agencies of mental health care (Lowry &
Ross, 1997).
Wells et al. ( 1996) reminds readers that for most practitioners, tracking psychotherapy
outcomes is becoming a requirement, not an option. This requirement not only stresses the
efficacy of treatment but the importance of documentation of treatment decisions based on
treatment outcome studies. Burlingame et al. (1995) wrote "it is essential for health care
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providers to document clinical results (endpoint assessment) and employ procedures for
identifying and correcting problematic components of treatment through continuous ongoing
monitoring of patient care (i.e., continuous quality improvement [CQI])" (pp. 226-227). These
procedures have already been demanded for some time. Lambert and Brown ( 1996) wrote
The wholesale purchasers of health care services (employers, insurance companies,
government) are increasingly demanding that measurement of clinical outcomes be
incorporated into all aspects of health care delivery, and that treatment decisions are made
based on sound empirical evidence for efficacy and value rather than financial
considerations alone. (p. 176)
Regardless of new requirements to track patient progress in psychotherapy, there is a
growing realization among practitioners of the need to set themselves apart as professionals. ln
this regard, Lambert. Ogles. and Masters ( 1992) wrote "Whereas the charlatan relies on selected
case testimonials to justify using marginal treatments, the professional counselor understands his
or her ethical obligation to provide objective evaluation of the quality of service" (p. 527).
Treatment decisions are likely to be most appropriate when they originate with the service
provider. Lowry and Ross (1997) stated "psychologists are guided by professional ethics to
provide a necessary and sufficient amount of psychotherapeutic intervention to adequately treat a
client's problem(s)" (p. 272). The goal of improvement of services can only aid in the process of
ensuring future practitioners' management of their care. increased quality of care, based on
effective interventions, will allow therapists to regulate treatment conditions better and avoid
third-pany payment struggles. Johnson and Shaha ( 1996) wrote
Developing quality improvement models allows professional psychology to undo the
disastrous mistakes of the past of opposing managed care (psychology's opposition to
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managed care only marginalized the profession and certainly did not contribute to any
resolution of the problems with managed care). Continuous Quality Improvement will
promote effective treatment options based on results of treatment. (p. 227)
Low-cost systematic measurement of treatment effects by the practitioner will establish a basis for
treatment decisions made by him or her.
In addition to the above, managed care has put brief intervention models at the forefront of

treatment modalities. This emphasis on cost-effective therapy is not all bad, however, and can be
used to provide prescriptive treatments that bring lasting change. Even psychologists agree that
1here are some problems that can be effectively treated in relatively few psychotherapy sessions.
Lowry and Ross ( 1997) wrote
The findings suggest that situational (e.g., work difficulties, adjustment disorder) or
symptom-based (e.g., sleep problems, simple phobia) problems are expected to require
significantly less psychotherapeutic intervention than relational problems or personality
problems. Moreover, disorders typically viewed as biologically based (e.g.. schizophrenia)
were considered as requiring the largest number of psychotherapy sessions or were
considered untreatable by psychotherapy alone. (p. 276)
Some clients feel that less counseling is preferable and sufficient (Warner, 1996). In such
cases, service providers can limit the number of sessions needed to reduce symptoms and ensure
gains. Salzer, Bick.man, and Lambert ( 1999) affirmed that "the relationship between number of
outpatient psychotherapy sessions and clinical outcome has become a focus of attention" {p.235).
This kind of approach is crucial if future therapists want to market their skills effectively. Going
beyond "good-enough therapy," this type of patient-service considers the cost of treatment and is
more responsible for it.
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Client attrition, dosage limits, and average length of treatment have all been considered
when making ueatment decisions. Phillips (1988) wrote "Today, more and more psychotherapists
think in terms of planned short-term treatment--whether using a 6-session (the most common). 16session, or 26-session mode" (p. 669). Treatment duration decisions have also been influenced by
client diagnosis. therapist theoretical orientation, therapist age, experience, and gender (Lowry &
Ross. L997). Furthermore. since many patients terminate so early in treatment, service providers
need to weigh carefully the amount of psychotherapy they recommend.
The concern of many practitioners is whether or not brief therapy will be intentionalized
(Steenbarger. l 992). The number of sessions prescribed must always be in the best interests of the
patients and must consider the patients' willingness and commitment to treatment. This can
become quite difficult with certain disorders. Franko and Erb ( 1998) wrote
The challenge of treating patients with eating disorders, together with the increasing
intrusion of third-party payers into the healthcare system presents a dual dilemma for
mental health clinicians. Although there are potent treatments for patients with anorexia
nervosa and bulimia nervosa, most therapies require substantially more than a brief
number of sessions in order to be effective. (p. 43)
Patients' mental health needs, symptom severity, risk, as well as financial means to pay for
treatment are a few of the factors that need careful consideration when treatment recommendations
are made. Often, clients are highly aware of their problems and are ready to form an alliance with
practitioners (Steenbarger, 1994). These clients can collaborate with their therapists to make some
decisions about the duration of treatment.
Service providers also need to inform their clients about treatment alternatives and
expected positive and negative outcomes, as well as recommend what is the best course of

Dose-Effect Relations

7

1rea1men1 for them. A s1udy done by Consumer Reports showed that clients who stayed in therapy
more 1han six months reported the most progress and those who began therapy with more serious
problems reported the best outcomes after staying in therapy for two years (Gurin, 1995).
Seligman ( 1995) wrote about the results of the Consumer Reports study, "Long-term therapy
produced more improvement than short-term therapy. This result was very robust, and held up
over all statistical models" (p. 968). As symptom severiry increases, clinicians and third party
payers must be open to more treatmem. As has been staled above, ongoing assessment of
treatment ou1comes can help practitioners increase their effectiveness and maintain control over
treatment decisions. Lambert and Brown ( 1996) wrote
There is no doubt that standardized monitoring of patient progress will further
demonstrate the value of psychotherapy and lead to greater understanding of just how and
when it is most and least effective. We look forward 10 the time when clinicians routinely
and sys1ematically gather and share information about the effects of their work, blending
the best of the art and science of psychotherapy. (p. 177)
[mprovement over Various Durations
Other studies have looked at the percentages of patients improved for various amounts of
psychotherapy. Howard, Kopta, Krause, and Orlinsky, (1986) wrote
By eight sessions. 48% to 58% of patients would be expected to have measurably
improved. About 75% of patients should have shown measurable improvement by the
end of six months of once-weekly psychotherapy (26 sessions) and about 85% by the end
of a year of treatment. (p. 162)
One study of the benefits of differing doses of psychotherapy on college students found that 11 %
of the college students reported improvement on interpersonal relations after 2 to 5 sessions, this
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increased, however, to 38% for those completing 11 to 20 sessions (Weitz et al., 1975).
Furthennore, the length of therapy has been found to be a significant predictor of improvement.
particularly for the less severe mental and emotional conditions (Knesper, Belcher, & Cross,
1987).
Another study of clients seen at a college counseling center found a strong linear
relationship between the proportion of clients improved and treatment length up to about 20
sessions (Strassberg et al., 1977). Salzer et al. ( 1999) stated that dose-effect studies such as the
ones above have had a tremendous influence on the mental health field and have encouraged other
dose-effect studies. If clinicians or managed care organizations are rigid about lengths of time for
treatment, some clients may never get the help they need. One study surveyed l,000 members of
American Psychological Association Division 29 (Psychotherapy) and found psychologists
expected 30 to 40 sessions of individual psychotherapy to achieve clinically significant change
(Lowry & Ross, 1997).
As can be seen from the above-mentioned studies, many clients need more than eight
sessions co demonstrate measurable improvement. For example, Steenbarger ( 1994) has found in
his review of brief therapy that
Clients who are highly aware of focal problem patterns and fonn a ready, involving
alliance may benefit from symptom-centered, prescriptive interventions that achieve their
goals within 8 to 10 sessions. Within this group and over this limited span, there appears
to be a strong relationship between duration and outcome, and considerable evidence that
enduring changes can be achieved. At the other end of the continuum, clients with
broad, diffuse, and poorly understood patterns and who need considerable time to form a
trusting alliance may benefit from an extended period of exploratory work that moves

Dose-Effect Relations

9

treatment to the limits of brevity and beyond. (p. 116)
This seems to support cost management when clients are appropriate for briefer therapy. and. at
the same time. supports therapists trying to best meet the needs of their clients when larger
amounts of psychotherapeutic interventions are needed. One study found that even general
functioning increased with a longer duration of therapy. Seligman ( 1995) wrote
The advantages of long-term treatment by a mental health professional held not only for
the specific problems that led lo treatment, but for a variety of general functioning scores
as well: ability to relate to others. coping with everyday stress, enjoying life more. personal
growth and understanding, self-esteem and confidence. (p. 969)
There is a current need for ongoing research in psychotherapy dose-effects. The need for
increa~ed
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quality of services dictates that practitioners learn from the services they provide and

better customize interventions. Information can be shared with other providers to ensure

maximum effectiveness of treatment and the avoidance of premature discontinuation or excess
where not needed. Herron, Eisenstadt, Javier, and Primavera ( 1994) wrote "If session
effectiveness research becomes more extensive, sophisticated, and comparable, it could be a
valuable tool for more informed decisions by policy makers, funders, consumers, and providers"
(p. 284).

The trend toward managed care involvement in decisions must alert practitioners to
continue to seek effective interventions and psychotherapy amounts. Franko and Erb (1998) stated
In reality, most [insurance] plans offer four to eight sessions and the authorization of

additional visits requires a substantial crisis or life-threatening behaviors. Therapists are
required to manage patients in increasingly less time and are pressured by third-pany
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payers to do so or risk being denied further referrals. (p. 44)
Measuring treatment efficacy across visits will increase as third-party payers seek to maximize
their service-to-cost ratio (Umphress, Lambert, Smart, Barlow, & Clouse, 1997).
It seems certain at this point that the very diversity of challenges that face therapists will ensure no
one appropriate dose for all. Steenbarger ( 1994) wrote "The present review raises the possibility
that there is no one function linking duration and outcome across all clients, concerns, and helping
approaches" ( 117).
Brief Therapv

It is difficult to study dose-effects of psychotherapy without being impacted by brief
therapy. This treatment model seems to be the goal of many of the funders of mental health
services. Limits on insurance coverage for psychotherapy have always existed (Herron et al..
1994) and so this should not alarm us. ln fact, financing problems of health insurance companies.
a growing demand for psychotherapy, and the restricted number of psychotherapists have all
contributed to the development of short-term psychotherapies and their standardization (Kordy,
Von Rad, & Senf, 1988). Brief ueatment models have also gained support from clinicians who
need to stay on provider panels and demonstrate cost effectiveness to managed care organizations.
At times, even patients seem to advocate for brief therapy. "Spontaneous remission" seems
to illustrate this. Howard et al., (1986) wrote "Our meta-analysis suggests that about 15% of
patients will feel and/or show measurable improvement before attending the first session of
psychotherapy" (p. !63). Many times situational or symptom-based problems can be treated
effectively in a relatively short duration. Because brief therapy has been, at times, unfairly
compared with other treatment modalities of longer duration, it has been viewed as lesser by some
practitioners. Steenbarger (1992) wrote
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Given that brief therapy is viewed as less effective than time-unlimited treatments for most
clients, it would not be surprising if therapists tended to underestimate the effects of such
work relative to the ratings of clients and neutral observers. This. in fact, appears to be
the case. (p. 54)
This is unfortunate as brief therapy can be an effective intervention for various problems. Herron
el al. ( 1994) wrote "Given a particular goal, such as symptom removal, brief psychotherapy may
do as well or beuer than unlimited psychotherapy. That does not mean that shon-term and longterm therapies are interchangeable or that they have identical results" (p. 283).
In summary, outcome studies have been a part of mental health l.l'eatment for a long time

and have been used for a variety of reasons. Recently, changes within both mental health and
health insurance companies have contributed to the use of outcome studies to investigate the issues
of treatment duration and the quality of patient care. The practitioners who deliver these services
seem to be both frustr:ited and stimulated by these challenges and would like to demonstrate a high
degree of professionalism in these matters. Therapists are also concerned that brief therapy will be
imentionalized for reasons of cost containment and the best interests of the patient will be
secondary. As for the literature in this area, many studies have supported !he efficacy of
psycho1herapy and the benefits of it in larger amounts for some patients while other studies have
found brief l.l'eatment to be sufficient for problems such as symptom removal. It seems that shortlerm and long-term therapies serve unique functions for distinct populations.
Given the inconsistencies in the research findings regarding the effectiveness of timelimited therapy. the author decided to conduct an outcome study of varying amounts of
psychotherapy. It is necessary to understand dose-effects so that treatment decisions can best be
made. ethical standards can be met, and quality of service can increase. Specifically, the aim of
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this study was to investigate the effects of varying doses of psychotherapy given over a I 0 week
period to undergraduate students who served as analog psychotherapy patients. These varying
doses of psychotherapy were the independent variables in this study. The dependent variables
were the symptoms of the participants in the study as they reported them on the OQ-45.11.
Four research questions were addressed by this exploratory study. First. what, if any, is the
rate of change in reponed symptoms by a group of "normal" undergraduates exposed to IO
sessions of psychotherapy? Second, if the psychotherapy does reduce the subjects' symptoms, are
I 0 sessions more effective than 5 at doing so? Third. is there a linear relationship that can be seen
for the effect of the psychotherapy on the subjects' symptoms? Fourth, did gender affect the
outcome within the treatment group. and, if so, in what way?
Hypotheses
Three hypotheses were tested in this study: (I) Subjective Well-Being scores (as measured
by the Outcome Questionnaire-45.11) for the treatment group will be significantly lower than
those of the control group on the mid and post-tests. (2) Subjective Well-Being scores will be
lower for the treatment group subjects tested after five, and ten sessions of individual
psychotherapy than the scores of the same subjects on the pretest. (3) Subjective Well-Being
scores will be lower for the treatment group subjects tested after ten sessions than the scores of the
same subjects after five sessions.
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Chapter 2
Method
Participants
Participants included college student volunteers serving as analog individual psychotherapy
clients for first-year students in a doctoral clinical psychology program. The sample of 60 students
was taken from a Northwest university. Ages ranged from 18 years to 20 years. The gender
composition was approximately 56% female and 44% male with most of the participants being
Caucasian. The participants tested were currently enrolled in an Introduction to Psychology class
and received research credit for their participation in the individual psychocherapy.
The experimental group was fonned by taking the weekly schedules provided by the
participants interested in the psychotherapy. giving them to the graduate student trainees, and
having the trainees contact participants whose schedules would aHow the trainees to meet with
them on a weekly basis. The control group was fonned by asking the students of 4 Introduction to
Psychology classes to take the Outcome Questionnaire-45.11 and other measures. Although the
Religious Orientation Scale and an Experimental Measure of Religious Practices were also
administered, this study did not utilize those data. Research credit was provided for those students
who compleced the measures all three times. They were administered over a twelve-week period.

Measures
Treatment effects were assessed by means of the OQ-45. l L The OQ-45.11 is a 45-item
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measure that includes items that assess subjective discomfon, interpersonal relationships, and
social role performance (Burlingame, Hansen, Larnben, Lunnen, & Umphress, 1994). These areas
represent how persons feel, how they are getting along with significant others, and how they
are doing in imponant life tasks such as work and school (Burlingame et al., 1994). Each item is
responded to on a five point Liken continuum from Never to Almost Always. The OQ-45.11
measures patient progress in therapy and was designed to be repeatedly administered during the
course of treatment and at termination. Gross treatment assignment decisions can be made from
the OQ-45. l l as it was designed to be used as a baseline screening instrument. Nonna! scores for
Undergraduates on the OQ-45.11 are: Subjective Distress - 23.08, Interpersonal Relations - 8.95,
Social Role - 10.37, and Total - 42.4.
The OQ-45.11 was chosen for this study over other measures for its brevity (taking onehalf the time of similar measures), its breadth of use, as well as its sensitivity to change over short
periods of time while maintaining high levels of reliability and validity (Wells et al.. 1996). The
co-efficient for internal consistency of the OQ-45.11 Total score is .93, and the test-retest
reliability is .84. The co-efficients for validity are .7824 with the General Symptom Index of the
Symptom Check List-90-Revised, .7959 with the Beck Depression Inventory, .8625 with the
Taylor Manifest Anxiety, and .6449 with the Social Adjustment Scak.
The OQ-45. 11 is a broad measure as well, designed to assess common symptoms across a
wide range of mental disorders and syndromes including stress related illness and V. codes
(Burlingame et al., 1994). Although the OQ-45.ll is a face-valid test, and could be distorted
consciously, the participants would have received no benefit from doing so.
Procedure
The participants for the treatment group were selected by the graduate students
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conducting the psychotherapy. The graduate students were told to select one female and one
male participant to ensure counseling experience with each gender. The graduate students chose
panicipants whose schedules were similar to theirs so !hat finding times to meet together would be
easily facilitated. Of the participants left in the sample, 62 were assigned to the control group as
they had completed the OQ-45.11 all three times it was administered. Twenty-three of the
participants served in the treatment group with similar numbers of males and females in each
treatment and control group.
The participants were given the OQ-45.11 three times: 1) before beginning psychotherapy,
2)

after five sessions, and 3) following ten sessions of psychotherapy. The measure was given to

the treatment and the control group participants by their Introduction to Psychology instructors all
three times. The participants were selected out of 4 classes taught by 4 different instructors.
lnfonned consent was collected by the instructors during the first administration of the measure.
All participants were selected, treated, and tested within a twelve-week time frame to minimize
"history" effects.
Participation in the study was voluntary. Participants were given information regarding
involvement in the testing and how the experience may have affected their treatment. Because
assessment was done in the classroom and not overtly linked with the treatment, the experience of
the testing is expected to have little, if any, effect on treatment. Participants were instructed that
no negative repercussions would result from declining to participate except that the treatment
group would not receive research credit if they did not complete the psychotherapy. Attempts
were made to encourage all of the participants to remain in the study.
The participants were assured anonymity and confidentiality of all responses. Each
participant was given a number. All data was identified by tile number only. The author kept the
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master list of names and numbers as well as all consent fonns. When all the data was collected,
the list of names and numbers was destroyed. Participants were told that all responses were for the
purposes of "training a graduate student in clinical psychology." Participants were given the
option to discontinue at any point.
Directions for completing the OQ-45.11 are printed on the answer sheet. The test
administrator(s) encouraged the participants to fill out the scale in an honest and conscientious
manna and complete all items. The average time required for taking the OQ-45.11 is less than ten
minutes.
The treatment process consisted of the trainees meeting with their client one time per week
for fifty minutes. The trainees were first year graduate students and were using basic counseling
skills rather than a particular therapeutic orientation. The focus was on attending, listening,
understanding, basic empathy, probing, summarizing, challenging, and helping clients plan and
work for what they wanted. The manual that was used to train the graduate students for this
experience was Exercises in Helping Skills, (6th ed.) by Gerard Egan (1998).
The trainees were supervised by either the professor teaching the counseling skills class or
one of two graduate assistants. The supervision hour consisted of groups of three trainees meeting
with their supervisors and sharing audio or video recordings of themselves with a client. They
were asked to share instances of themselves demonstrating specific skills as well as difficulty and
success at helping the client. A critique of the skills and ideas for further work with the client was
shared by the supervisor.
Statistical Analysis
The above-mentioned three level design utilized an analysis of variance with repeated
measures to test for the significance of the independent variable, psychotherapy (Brase & Brase,
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1995). The data was read into SPSS and descriptive data was used co make group and occasion
comparisons. A 2 X 3 multivariate analysis of variance with repeated measures (treatment vs.
control groups, pre, five week and ten week outcomes) was used to compare this data.
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Chapter 3
Results

Of the l 35 participants who completed the OQ-45 .11. 57 ( 42%) failed to complete it all
three times: 48 of these 57 participants were in the control group and were removed from the
study. The remaining 9 were in the treatment group and l of the 9 was removed from the study as
he/she had failed to take the OQ-45. l l during either the first or second administration. An
additional treatment group participant was not included in the study as he/she was referred for
additional treatment. Of the 23 participants in the treatment group, 10 (43%) were male and 13
(57%) were female. Of the 62 participants in the control group, 28 (45%) were male and 34 (55%)
were female.
The OQ-45. l l is a screening measure that includes

item~

assessing subjective discomfort,

interpersonal relationships, and social role performance. It yields scores for subjective distress,
interpersonal relations, social role, and has a total score. These four scores provided the data to be
analyzed. Figures 1-4 represent each of these domains at the pre-test, mid-test and post-test for the
treatment groups. Descriptive statistics for each of the main variables are included in
Table I.
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Table I
M~ans

illld Stillldar~ Deyfati2~ QD OQ4S, 11 fQc I~llD!:Dl and C201ml GUU.!l!li b)'. Oci;asi2os

Variable

Group

Gender

Mean

Symptom
Distress I

Treatment

Male
Female
Total
Male
Female
Total
Male
Female
Total

26.75
29.63
28.19
25.50
23.44
24.37
25.78
24.62
25.15

16.lO
12.00
13.80
8.11
7.37
7.72
I0.14
8.62
9.31

8
8
16
28
34
62
36
42
78

Male
Female
Total
Male
Female
Total
Male
Female
Total

25.75
27.38
26.56
25.93
22.21
23.89
25.89
23.19
24.44

12.68
12.32
12.10
9.58
7.69
8.73
10.15
8.82
9.49

8
8
16
28
34
62
36
42
78

Female
Total
Male
Female
Total
Male
Female
Total

26.75
27.88
25.79
20.82
23.06
26.50
21.95
24.05

l 1.49
14.ll
9.52
8.03
9.01
l 1.41
8.94
10.34

8
16
28
34
62
36
42
78

Control

Total

Treatment

Control

Total

N

---------·--------·-----·-----

__ .......... - .. ------------------ ...
Symptom
Distress 2

Standard Deviation

----------·--------------·------------------------------·-··8
29.00
17.08
Male
Treatment
Symptom
Distress 3

Control

Total

-------------------------

Table Continues
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Table l Continued

Variable

Group

Interpersonal Treatment
Relations I
Control

Total

Standard Deviation

N

Gender

Mean

Male
Female
Total
Male
Female
Total
Male
Female
Total

7.75
4.60
6.16
5.24
3.83
4.77
5.76
4.12
5.10

8
8
16
28
34
62
36
42
78

Male
Female
Total
Male
Female
Total
Male
Female
Total

10.88
10.38
10.63
10.46
7.24
8.69
10.56
7.83
9.09
... .......... .....
13.00
8.25
10.63
9.46
6.79
8.00
10.25
7.07
8.54

9.32
5.06
7.65
4.83
3.07
4.15
6.13
3.51
5.12

8
8
16
28
34
62
36
42
78

Male
Female
Total
Male
Female
Total
Male
Female
Total

11.25
10.25
10.75
9.39
6.88
8.02
9.81
7.52
8.58

9.22
5.28
7.28
4.89
3.21
4.21
6.0l
3.85
5.06

8
8
16
28
34
62
36
42
78

Male
Female
Total
Male
Female
Total
Male
Female
Total

11.38
10.94
11.04
8.59
9.69
10.92
9.12
9.95

3.96
3.49
2.63
3.41
3.30
2.72
3.64
3.35

8
16
28
34
62
36
42
78

---------------------------------·---------------- -- - ------·-----------------Interpersonal Treatment
Relations 2
Control

Total

-----------·-------------------------------------------Interpersonal Treatment
Relations 3
Control

Total

---------------------------------------------------------8
Social
10.50
3.16
Treatment

Role 1
Control

Total

----------------------------...

------------Table Continues
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Table I Continued
Variable

Group

Gender

Mean

Social
Role2

Treatment

Male
Female
Total
Male
Female
Total
Male
Female
Total

11.25
9.75
10.50
I 1.18
8.71
9.82
11.19
8.90
9.96

2.82
3.58
3.69
3.23
3.64
3.48
3.28
3.54

8
8
16
28
34
62
36
42
78

Male
Female
Total
Male
Female
Total
Male
Female
Total

l l.88
12.25
12.06
11.71
7.91
9.63
11.75
8.74
10.13

4.91
3.24
4.02
3.11
3.04
3.60
3.51
3.49
3.79

8
8
16
28
34
62
36
42
78

Male
Female
Total
Male
Female
Total
Male
Female
Total
...

48.13
51.38
49.75
47.00
39.26
42.76
47.25
41.57
44.19

25.90
18.91
21.97
13.52
12.87
13.62
16.59
14.75
15.78

8
8
16

34
62
36
42
78

Male
Female
Total
Male
Female
Total
Male
Female
Total

50.00
45.38
47.69
46.57
37.71
41.71
47.33
39.17
42.94

23.65
18.83
20.79
15.26
12.45
14.38
17.14
13.95
15.93

8
8
16
28
34
62
36
42
78

Control

Total

Standard Deviation

3.20

N

---------------------- .................-------------------------------------------·----------Social
Role 3

Treatment

Control

Total

----------------------------·--------------·-------

Total I

Treatment

Control

Total

.......................... _________________
Total 2

Treatment

Control

Total

.....

28

_________________________________

-----------------------------·-------

Table Continues
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Table I Continued
Variable

Group

Total 3

Treatment

Gender

Mean

Male

52.13
49.25
50.69
46.89
35.62
40.71
48.06
38.21
42.76

Standard Devialion

N

28.26
8
17.47
8
22.74
16
Control
15.15
28
13.02
34
15.01
62
Tola!
18.48
36
14.76
42
78
17.20
----- ................................... _________________________.. _______________________ .. .,.___________________
,. ______
Female
Total
Male
Female
Total
Male
Female
Total

The first research hypothesis concerned how 10 sessions of psychotherapy would affect
the rate of reported symptoms of a group of undergraduates. An analysis of variance with
repeated measures revealed no significant treatment effects across ad.ministrations of the 0Q-

45.11. There were no significant group effects when the treatment group was compared to the
control group at the pre-therapy, f(l,74)=2.996, 12.=.088; and post-therapy testings,

.E( l,74)=1.605, 12.=.209; and oo significant occasion effects. f(l,74)=1.751, p.=.190. However
the lnterpersonal Relationships scale was close to significance, f(l,74)=3.553, 12.=.063; and a
significant gender effect was observed, f(l,74)=4.029, J;!.=.048. No time (occasion) by group
interactions were found, f(I, 74)=.988, 12.=.324; and no ume by group by gender interactions.

(E(2,148)=3.404; 12.=.036).
The second research hypothesis investigated the differences between the treatment group's
symptoms at pretest and at 10 sessions. No main effects for treanneot were found, f(l,19)=.140,

12.=.712. Chi-square analyses were performed and the Interpersonal Relationships scale,
.E(l, I9)=3.446, ~.079, was near significance. The Subjective Distress scale, f(l, 19)=1.069,
~.314;

Social Role scale, E(l,19)=2.165, ~.158; and Total scale, f(l,19)=2.073, w.166 were
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not significant.
The third research hypothesis addressed whether or not there was a linear relationship that
could be seen for the effect of the psychotherapy on the subjects' symptoms. An analysis of
variance with repeated measures again revealed no significant treatment effects across
administrations of the OQ-45.11, f(l,19)=1.999, I!=.174.
The final research hypothesis was interested in gender and if it would affect the outcome
within the treacment group. A 2 X 3 multivariate analysis of variance with repeated measures
revealed that there were no main effects for participants' gender. However, when time was
compared to group and gender, a significant linear effect for time by gender interaction was found
on the Subjective Discomfon scale, f( 1,74)=5.56, 2.=.022; and significant quadratic effects were
found on the Interpersonal Relationships scale, f(l,74)=5.379, 2.=.023. for time, group, and
gender. Significant quadratic interactions were also found for time by group by gender for
Interpersonal Relationships, .E=6.568, 2.=.012, and for Social Role, f=4.372, I!-=.040. Results of
analysis of variance for each of the main variables are included in Table 2.
Tre~tment

Groups Compared

There were no differences found between participants in the treatment group who
completed the OQ-45.11 all three times and those who did not on the Subjective Discomfort scale,

f( I, I9)=1.069, Q.=.314; Social Role Performance scale, f(l,19)=2.165, Q.=.158; or Total scale,
.E< t, t 9)=2.073, 2=.166. Although there were no significant group effects found when the two
treatment groups were compared, there were three quadratic effects and interaction effects found,
time by gender for Interpersonal Relationships, f(l,19)=5.379, I!=.023; time by group by gender
for Interpersonal Relationships,

f( l, 19)=6.568, X?=.012; time by group by gender for Social Role,

E< I, l 9)=4.372, £!:;:.040; and time by gender for Subjective Disuess.
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Table 2

Results of Analysis of Variance for IreatmeDI and Control Groups by Occasions

Source

Intercept

Measure

df

SD

IR

SR
TOTAL
GROUP

SD
IR
SR

TOTAL
GENDER

SD
IR
SR

TOTAL

Mean Square

F

Sig. off

100955.111
13803.178
16829.139
319166.737

408.780
244.624
681.371
484.443

.001
.001
.001
.001

491.924
200.475
65.441
1973.837

1.992
3.553
2.650
2.996

.162
.063
.108
.088

76.311
227.323
85.161
1091.715

.309
4.029
3.448
1.657

.580
.048
.067
.202

178.591
4.934
75.934
590.441

.723
.087
3.074
.896

.398
.768
.084
.347

--------··----------------·-··-----------------·-GROUP*GENDER
SD
IR
SR

TOTAL
Error

SD
IR
SR

TOTAL
~

74
74
74
74

---··--

246.967
56.426
24.699
658.832

SD =Subjective Distress, IR= lnterpersonal Relations, SR= Social Role

26
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Sample Means Compared
Students t tests measured whether the sample means differed from the nonnative means
and the results are included in Table 3. There were no differences found between the normative
means for normals and the sample means.

Table 3
Results oft Tests Comparinii Sample Means wjth Nonnatjye Means from the OQ-45 I I

Measure

Normative Mean

Symptom Distress
Interpersonal Relations
Social Role
Total

23.08
8.95
10.37
42.33

Sample Mean

Significance

25.15

l.648

9.09
9.95
44.19

.208
.976
.887

NS
NS
NS
NS
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Chapter 4
Discussion

ln general. the results of this analog study of treatment effects do not support the
hypothesis that Subjective Well-Being scores of the treatment group would be significantly higher
than those of the control group on the mid and post tests (Hypothesis 1). There was no significant
group effect when the treatment group was compared to the control group at the pre-therapy and
post-therapy testings and no significant treatment effects across administrations of the OQ-45. l l.
Symptoms were found to be unchanged at the end of the testing or post administration for all the
participants. It is unknown what accounts for these effects. One cause may have been the
semester that the student panicipants were in. They may have been affected by the spring break
that took place near the mid-test. The end of the semester may have also increased their feelings
of subjective distress as finals were soon to be taken.
Furthermore, both the treatment and control subjects were taken from an analog sample.
The scores of the treatment and control subjects were all normal, and this may have reduced the
amount of possible treatment effects before the independent variable, psychotherapy, could be
administered. It seems that this study needed a clinical sample to administer the psychotherapy to
for treatment and control groups.
Hypothesis 2 was not supported by the results either. Subjective Well-Being scores were
not higher for the treatment group subjects tested after five, and ten sessions of individual
psychotherapy than the scores of the same subjects on the pretest. A 2 X 3 multivariate analysis
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of variance with repeated measures revealed no significant treaunent effects. Again, this may have
been a result of using a non-clinical analog sample for the treatment group. The treatment groups'
symptoms were not very high to begin with (pretest symptoms) and so clinically significant change
was difficult to attain.
The results of this study do not support hypothesis 3 that Subjective Well-Being scores will
be higher for the treatment group subjects tested after ten sessions than the scores of the same
subjects after five sessions. An analysis of variance with repeated measures again revealed no
significant treatment effects across administrations of the OQ-45.11. Time was found to not be a
significant variable a-; there were no overall simple linear effects.
Gender was also found to have no effect on the outcome within the treatment group. A
2 X 3 multivariate analysis of variance with repeated measures revealed that the participants'
gender did not predict outcome. However, when time was compared to group and gender, there
were interaction effects. lt is not clear what may have caused this. Interestingly, there was a
quadratic effect on the lnterpersonal Relationships scale and a quadratic effect was found.
indicating a time by group by gender interaction on the Social Role Performance scale.
Treatment Groups Compared
The results of this study do not support differences between participants in the treatment
group who completed the OQ-45.11 all three times and those who did not. Chi-square analyses
were performed and the Interpersonal Relationships scale approached significance. Although there
were no significant group effects found when the two treaunent groups were compared, there were
three quadratic effects and interaction effects found.
One interesting finding was that the participants in the study indicated a very similar
response to item #17, "I have an unfulfilling sex life." While the majority of the participants
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marked "Never" as their response, many of them wrote a note next to the item that indicated they
do not participate in sexual behavior. As most all the participants are not married, this common
response seems to point to the behavioral health of the sample. Perhaps this sample is not only
non-clinical, it may be considerably healthy. The treatment group was pulled from this sample and
their self-report symptoms were quite low as they began the psychotherapy. Reducing symptoms a
significant amount in persons that are already in a healthy range is very difficult.
Compariso::i of Normative and Sample Means
When a Student's t-test was used 10 compare the means of the nonnative sample of
undergraduates to this sample at pretest on the four scales no differences were found. This may be
a result of comparing one relatively healthy group to another. It is likely that both of these
undergraduate samples represent groups of people with very few clinical symptoms.
Limitations
Although this current investigation attempted to understand the significance of dose-effect
relationships in psychotherapy, several limitations of this study should be considered. The
graduate student conducting the research served as a direct supervisor of the first-year doctoral
students and his participation in the research may have affected psychotherapy outcomes in the
college students. In addition, the first-year doctoral students' psychotherapy experience was varied
and so may have had an unknown effect on the outcomes.
Perhaps the most significant limitation in the present study was the sample. Specifically,
the treatment group was an analog sample of mostly healthy college students. This might have had
the effect of limiting the amount of symptoms that could be reduced. For treaunent effects to be
demonstrated a significant amount of change is necessary; the notmal pre-treatment scores of this
sample made it difficult to measure any effects of the independent variable, psychotherapy.
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Another limitation of this study might be in its specificity. The sample of undergraduate
general psychology students at George Fox University may not represent the young-adult
population as a whole. Participants in this study were largely Caucasian. Given the religious
nature of the instimtion, we can assume that the majority of the panicipants were Christians. Due
to

their faith, many of the participants may not engage in substance abuse, sexual indiscretions, or

hnve thoughcs of ending their life. All three of these issues appear on the OQ-45. l l (five times)
nnd can affect one's overall score of sympcoms.
These results apply to self-referred college students who had been offered class
credi! for their participation in the study. Results might differ in outpatient clinics. hospitals or
other non-academic settings. Finally, this study pertains only to the dose-effect relationship in
ndult psychotherapy. and the results may not generalize to child psychotherapy.
Suggestions for Future Research
Treatment outcome studies are essential to clinical decision making and guaranteeing costeffective care (Mirin & Namerow, 1991 ). The issue of treatment duration and optimal length has
become a central focus recently. The present study attempted to address this issue, but the power
of the study was diminished by the sample. Future dose-effect studies may benefit from taking
their treatment group from a clinical sample. Using a more diverse sample would also be a better
representative of the greater population. A larger sample would increase the power of the
stmistical tests.
Many scudies described their favorite length of therapy and could cite much research to
substan!iate their views. For example, some have used the Consumer Reports study to make a
case for a longer duration of treatment (Gurin. 1995). It seems as though treatment duration has
become political and the studies being done are to back up ones' views and not to find what is best
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treatment. It would be best if those who conduct dose-effect studies would be open to more or
less therapy for any particular problem and would avoid seeking to prove a particular treatment
duration is optimal.
Conclusion
Although this study did not support the hypotheses that were established, it did provide
valuable insights on how and how not to conduct a dose-effect study. The study reminds us of
the value of a sample and how a analog sample can limit the possibility of clinically significant
change. It is difficult and time-consuming to conduct treatment outcome studies. I hope that this
study will encourage others to pursue treatment outcomes. As a result, mental health
professionals will be better equipped to make treatment decisions in a professional manner.
It is recommended that future studies use a larger sample. Having the first-year students
in the doctoral clinical psychology program counsel three or four college student volunteers per
week would make that possible. It is also recommended that the study examine whether the
analog therapy experience contnbutes to increased reporting of symptoms. The final
reconunendation is that the participants be split into a group of normals and clinicals at the outset
of the study.
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Informed Consent for Participation
- - - - - - - understand lhal I am participating in a research project for lhe training of a
graduate student in clinical psychology. As a participant, I will be given the Outcome
Questionnaire (OQ.45.11) three times. In addition I will be given several survey questions rhat ask
about my attitudes and beliefs related lo social and religious beliefs and behaviors. I undersrand
that I may discontinue my involvement in the research at any time. I also understand that all data
will be kept confidential and only the graduate student conducting the research (Brian Whitehall)
and the faculty members involved in the research, Dr. Rodger Bufford and Dr. Kathryn Ecklund
will have access to my research data. I understand that there will be no reference to my name on
any of the testing material. I will be assigned a number by the graduate student conducting the
research who will protect my evaluation data from being attached to my name at all rimes.

Signature of participant:--------

Date: _ _ __

Participant Identification Number (to be placed on participant forms) _ _ _ __
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Data Code
Identification: columns 1-3
Sex: column 4 - Male - L. Female - 2, Missing data - 9
Group: column 5 - Treatment - I, Control - 2
column 6 & 7 - leave blank
Scores: columns 8-33
SD l - column 8&9
lRl - column 10&1 l
SRI - column 12&13
Total l - column 14& 15
Blank column 16
SD2 - column 17 & 18
lR2 - column 19 & 20
SR2 - column 21 & 22
Total:? - column 23 & 24
Blank column 25
SD3 - column 26 & 27
IR3 - column 28 & 29
SR3 - column 30 & 31
Total3 - column 32 & 33

The model is a repeated measures design and all data for a given participant are entered in
a single string (one row) and you do not need to duplicate demographic information or

ID#s.
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Raw Data
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Raw Data
25291 99999999 21141247 29131557
l 0711 13070323 99999999 23040835
14411 2311l246 2710124931051349
21411 1204 !026 17051436 17102047
17611 140205211405072611030519
18121 22091041 16050728 26081145
2071 l 49261287 49301392 55231795
21821 08020616 1003072099999999
30221 39091159 43101265 29061348
16821 21090939 17040930 17071135
16921 09030517 110305 l 9 99999999
05421 I 1040520 17101138 99999999
09511 541816884125158155281396
14911 26031140 15020926 99999999
17121 49181986 42161573 44161979
1251 l 15080932 22101143 18090936
05121 29050943 22060836 99999999
18221 2303 1440 25041140 99999999
09821 39091664 37071155 40141468
17721 14060828 11020619 09071127
18721 32170958 28150548 28190855
l 7411 27091147 l 7111038 25041039
2051 l 20090938 19080835 20080836
2092 l 2 I060936 25071345 21051137
09311 34100953 30090746 99999999
12911 99999999 99999999 99999999
08192 99999999 3 l !01354 35071355
13022 32 !00648 29110646 27100946
14022 24091043 23071545 16050728
13322 26060638 30081149 25070638
14612 2007 l l 38 23061039 11060926
14822 15031028 27091046 99999999
12722 23090537 l !030519 07030515
13612 19121142 22071342 22060937
11922 24080840 24081042 22070837
13512 391813705415178652111780
I0112 21080938 20081038 18031132
11712 34121561 3512146139081360
13212 26161153 2712115021101243
12312 22081040 22091142 22091041
12122 351411603212115599999999
12422 25060637 17060528 18060529
07922 31100748 29091048 26090944
20112 17060528 14060828 14080729
04422 331008513108094826070740
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03912
21322
04712
08812
08022
05812
08322
06512
13922
10212
l 1322
04112
03812
20222
21122
21222
21522
21022
12822
13 122
07712
07622
04822
07822
08712
07422
05522
08912
08512
05612
05212
09212
10022
08422
09722
08222
091 12
04222
20822
22022
12612
11612
14712
14222
11812
09412

39200968 38251174 99999999
15050828 15030624 15090529
21081140 29061045 28091451
150313319999999999999999
I !020619 09040417 06010310
06070720 29121051 99999999
12070524 13060322 99999999
22110942 14030724 22110841
43201679 37161669 99999999
38211978 41211880 99999999
21080938 20050833 24100842
45211783 99999999 42181474
38171065 37201067 41241580
l405l l30 l5l20835 19081037
38151366371ll15940101161
18041032 99999999 19060833
24060939 16040727 15040928
35041756 30061652 28091148
17050628 99999999 99999999
20061036 17031030 99999999
12030722 12031328 99999999
18090835 11050521 06030110
25110945 26090944 22120943
22101244 99999999 31141055
33181263 27191056 99999999
17040627 22040935 13020621
l408093 l 99999999 99999999
391312644315167441131266
28041244 20040731 27050840
12060725 17110836 99999999
19030628 21040934 99999999
22050532 23040835 25080841
24100943 24091144 23081142
28070843 99999999 99999999
13040926 99999999 28100846
53161180 99999999 99999999
14040725 99999999 99999999
20030629 22061139 15061132
15030422 09020516 10010415
24050837 19090836 21070634
17090834 99999999 99999999
240611412211104327081348
20050833 28050942 19031133
26101349 26071447 27070741
14061030 12091031 15110632
33161059 99999999 99999999
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05712
05322
07322
09912
21922
06222
05922
12022
15012
06722
06812
06912
06412
20412
10422
20312
04922
l 0522
16212
16722
16312
16012
16122
18312
165 12
18522
18412
15822
18812
13822
143::!2
14522
17822
04022
06622
19522
17222
18022
21612
09012
20692
21792
05192
05092
03792

16091237 1913144699999999
11050420 16030524 14030421
39171672 39111464 27101249
23201154 99999999 99999999
42131772 99999999 33131965
27091450 28091249 25091549
19030426 13050220 15040625
41181372 43191476 99999999
34211772 30162369 23121752
35171062 99999999 43191072
04010611 99999999 03050715
33171363 35031351 30111455
40111364 32091354 26081044
13191345 13150937 24091548
11040419 99999999 99999999
20091241 31181766 24081547
14001024 16021028 14050928
21061037 2205 1138 99999999
15090933 15070729 17071034
27141152 99999999 21051036
37191470 34121157 33121358
34180860 99999999 3012095 l
24091346 99999999 99999999
22021135 20041236 15041231
27061043 25060738 22061341
20060632 22050835 31060946
23111448 23150846 25090943
26030635 22030833 22060533
24071041 23081243 39241780
15030523 24050837 28070944
05020411 050104 LO 99999999
34071253 31111153 99999999
20081038 22080838 28081248
28121353 24110843 18090835
21041035 99999999 22051037
20050833 99999999 25091044
25141251999999992716ll54
33121257 34131057 35161263
22080737 99999999 12070625
36141565 30151055 99999999
99999999 99999999 40151469
99999999 99999999 25120946
99999999 99999999 29100645
99999999 99999999 14040927
99999999 99999999 38211574
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Appendix D
Vita
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Vita
Brian J. Whitehall
5881 Batterman rd.
East Wenatchee, WA 98802
Home: (509) 884-4572
sllabetihw@.wl.com
Education
1996-1999

Graduate School of Clinical Psychology: APA Accredited
George Fox University, Newberg, Oregon
Student in clinical psychology Psy.D. program

1994-1996

Graduate School of Clinical Psychology
George Fox University, Newberg, Oregon
M.A. in Clinir.al Psychology

1989-1993

Western Baptist College
Salem, Oregon
B.S. Psychology

Supervised Clinical Experience
7/99-6/00
1/00-6/00

7/99-12199

Cliniail lnternsbip
Northeastern Ohio Universities College ofMedicioe: APA Accredited
Portage Path Behavioral Health. Akron. OH.
Population: Adults
Duties: lndividual Therapy and Intake Interviews. Co-facilitated a Dialectical
Behavior Therapy group, a Partial-Hospitalization group, and a
Tramitiooal Support group. Developed treatment plans and worked with a
multi-disciplinary treatment team. Comprehensive assessments of
adults (Coguitive/IQ, Personality, and Cbaracterological ).
Supervisor: fm Mullen, Ph.D.
Massillon Psychiatric Center, Massillon, OH.
Population: Chronically Mentally ill Adults
Duties: Interviewed new patients and wrote evaluations. Individual Therapy.
Led a Stress-Management group and co-f.acilitated a Dialectical Behavior
Therapy group. Provided recommendations to multi-disciplinary treatment
team. Wrote treatment plans for patients with the psychiatrist.
Supervisors: David Aronson, Ph.D., ABPP and Phil Seille~ Ph.D.

9/98-4/99

9/96-6/97

9195-5196

9194-5195
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Practicum Ill {Total Hours: 400)
Lutheran Family Service, McMinnville, OR.
Population: Adults, families, children
Duties: Individual and Family Therapy. Co-facilitated two violence
prevention groups for men. Conducted intakes, provided treatment
recommendations and consulted with agency psychiatrist. Personality
assessment and therapy for low-income children and adolescents in an
outpatient setting.
Supervisor: Susan Means, Ph.D.
Practicum II (Total Hours: 533)
Oregon State Hospital, Salem, OR.
Population: Chronically Mentally ill Adults
Duties: Comprehensive assessments ofinpatienl adults with emphasis on
neuropsychological assessment (Cognitive/IQ, Psychosocial,
Characterological, and Neuropsychological). Individual and Group
Therapy (Drug and Alcohol, Symptoms Management with emphasis on
psychiatric rehabilitation). Risk assessment and screening process for a
forensic, minimum custody unit.
Provided ~omm:ndations to multi-disciplinary treatment team.
Supervisor: Brett Rogers, Ph.D.
Practicum I (Total Hours: 642)
Linn County Child and Family Services, Albany, OR
Population: Adults, fiunilies, children
Duties: Individual and Family Therapy. Co-fucilitated anger management
group for adolescents and their families in an outpatient mental health
clinic. Comprehensive psycbologic:al assessmenrs of children and
adolescents primarily presenting with ADHD, Conduct Disorder, or
SexuaJ Abuse at intake.
Supervisor: Paul Stoltzfus, Psy.D.
Prepractieom (Total Hours: 75)
George Fox University, Newberg, OR.
Population: Aduhs
Duties: Provided counseling to two undergraduate students.
Received clinical training including: clinical skills, psychosocial
assessment/hi.story, mental status exam, intake interview, treatment
plans, anger management, and critical inr.ident response.
Supervisor. Wayne Colwell. Ph.D.

Dose-Effect Relations

48

Other Work Experience

7/97-8/98

Mental Health Therapist Technician (Total Hours: 1,464)
Oregon State Hospital, Salem, OR.
Population: Adolescents, children
Duties: Paid Position. Counseled and assisted children and adolescents with
major mental illnesses. Docwnented on the treatment and progress of
patients. Problem-solved with co-workers regarding treatment decisions
and milieu management.
Supervisor: Enuna Alstott RN.

Research Experience
l 0/97-present Diss.-!rtation

2/98-5/98

Title: Dose-effect relations in simulated psychotherapy as measured by the
outcome questionnaire-45 .11.
Description: A treatment outcome study, this research examines the efficacy of
psychotherapy under varying doses, on the subjective well-being of University
students.
Chair: Rodger Bufford, Ph.D.
Status: Fina! Oral completed. Making final changes.
Anticipated date of completion: 3/0 I
Program Development
Assisted with development, implementation and consulting report
assessing faculty student relationships at George Fox University.

Teaching Experience

9/97-4/98

Graduate Assistant (Total Hours: 227.5)
Wayne Colwell, Ph.D.
PSY 530 Prepracticum Didactic
Duties: Paid Position. Assisted in the training of fourteen graduate
students. Taught basic assessment and counseling skills, ethics,
and self-awareness. Led two supervision groups, provided
feedback and evaluations to trainees.
PSY 531 Prepracticum Didactic
Duties: Paid Position. Provided supervision to seven graduate student
counselors providing individual therapy to undergraduate
students. Taught continuing development of counseling skills,
interventions, referrals, case conceptualization, and tennination.
Provided feedback and evaluations to trainees.

Professional Affiliations

American Psychological Association (Student Affiliate) 1994-present
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Professional Seminars
I0198 Using The 16PF In Clinical Practice
Michael Karson, Ph.D., ABPP
5198

Race And Racism In Psychotherapy
Alice Chang, Ph.D. & Nelson de Jesus, Ph.D.

4/98

Explicit, Implicit, Intentional Clinical Integration: Galileo and Wesley: Two old,
but ever-new integration models.
Newton Malony, Ph.D., ABPP

J/97

REBT

Albert Ellis, Ph.D.
I0196 False Memory
L Polanski, Ph.D.
4/96

Brief Therapy: Object Relations
Greggory, Hamilton. M.D.

4/96

Narcissistic Disorders
Ralph Klein, M.D.
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David Aronson, Ph.D., ABPP (330) 833-3135
Massillon Psychiatric Center
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Massillon, OH 44648
Phil Seibe~ Ph.D. (330) 833-3135
Massillon Psychiatric Center
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Jim Mullen, Ph.D. (330) 253-4 I 18
Portage Path Behavioral Health
340 S. Broadway
.<\kron, OH 44308
Rodger Bufford, Ph.D. (503) 554-2750
George Fox University
414 N. Meridian, #6146
Newberg, OR 97132
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Relevant Coursework
Core Courses:
Personality Theory
Childhood Development
Adolescence, Adulthood, and Aging
Learning
Legal, Ethical, and Professional [ssues
History and Systems of Psychology
Social Psychology
Statistical Methods
Research Design
6.utcome Evaluation
Systems of Psychotherapy
Community Mental Health
Abnormal Psychology
Clinical Theory and Practice:
Psychodynamic Psychotherapy
Cognitive Behavioral Psychotherapy
Family Therapy
Object Relations
Cross-Cultural Psychotherapy
Therapeutic Communication
Religious Issues in Psychotherapy
Substance Abuse
Psychology ofEmotions
Professional Issues
Human Sexuality/Sexual Dysfunction
Psychophannacology/Psychoneurology
Therapy with Women
Forensic Psychology
Group Dynamics
Child/ Adolescent Therapy
Geropsychology
Psychodynamic Integration Seminar
Clinical Assessment
Personality Assessment
Cognitive and Intellectual Assessment
Projective Assessment
Neuropsychological Assessment
Comprehensive Psychological Assessment
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